- $95.96bn
- $97.86bn
- $10.21bn
- 66
- 42
- 95
- 75
Annual income statement for CME, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5,066 | 4,997 | 7,218 | 10,854 | 10,209 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,246 | 1,644 | 2,004 | 2,143 | 2,199 |
| Operating Profit | 2,820 | 3,353 | 5,214 | 8,711 | 8,011 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2,722 | 3,374 | 3,490 | 4,154 | 4,541 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2,106 | 2,637 | 2,691 | 3,226 | 3,526 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 2,105 | 2,637 | 2,691 | 3,226 | 3,526 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2,105 | 2,617 | 2,657 | 3,186 | 3,482 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 5.87 | 6.35 | 7.4 | 8.86 | 9.67 |
| Dividends per Share | |||||
| Special Dividends per Share |